GlaxoSmithKline (NYSE:GSK) hit a new 52-week high Friday as it is currently trading at $47.53, above its previous 52-week high of $47.50 with 398,814 shares traded as of 9:45 a.m. ET. Average volume has been two million shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- GlaxoSmithKline (NYSE: GSK) hit a new 52-week high Friday as it is currently trading at $47.53, above its previous 52-week high of $47.50 with 398,814 shares traded as of 9:45 a.m. ET. Average volume has been two million shares over the past 30 days. GlaxoSmithKline has a market cap of $118.43 billion and is part of the health care sector and drugs industry. Shares are up 2.8% year to date as of the close of trading on Thursday. GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. The company has a P/E ratio of 14.1, below the average drugs industry P/E ratio of 14.5 and below the S&P 500 P/E ratio of 17.7.
ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, notable return on equity, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. You can view the full GlaxoSmithKline Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.